Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode

August 24, 2021 updated by: Yusuf Ziya ÇOLAK, Inonu University

Anesthetic Cost Analysis With Desflurane in Automated Gas Control Mode With Maquet Flow-i Anaesthesia Machine

Inhalation agents constitute the major part of anesthetic drug costs (20% - 25%) and a significant portion of the applied inhalation agents are thrown into the atmosphere through the waste gas system without being absorbed by the patient. The amount of waste gas is directly correlated to the fresh gas flow (FGF). Reducing the TGA during general anesthesia reduces the consumption of inhalant agents and contributes to the reduction of greenhouse gas pollution. Risks such as hypoxia, hypercapnia, inadequate depth of anesthesia and potential toxic gas accumulation were associated with low flow anesthesia, but the patient was provided with adequate safety by following pulse oximetry, capnography, FiO2 and anesthetic gas analysis. We aimed to perform anesthetic cost analysis and patient security in automated gas control mode (AGC).

Study Overview

Status

Completed

Conditions

Detailed Description

After the ethical approvel 60 adult patients scheduled for hepatectomy will be taken to study. Patients will be monitored after they are taken to the operating room (ECG, NIBP, SpO2, Body Temp, BIS, NIRS, PVI, PI, ORI). After the anesthesia induction and tarakeal entubation, first twenty patient will take 300 mL fresh gas flow with AGC mode (group 1), Second twenty patient will take 600 mL fresh gas flow with AGC mode (group 2), third twenty patient will take 600 mL fresh gas flow with manually. Hemodynamic and gas consumption data will be recorded. An operating room will be reserved for this study.

Study Type

Observational

Enrollment (Actual)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Malatya, Turkey, 44280
        • Inonu Univercity

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing hepatectomy operation

Description

Inclusion Criteria:

  • Adult patients undergoing hepatectomy with general anesthesia

Exclusion Criteria:

  • Essential data missing
  • Patient participating in other research projects
  • Drug allergy
  • Anesthetic complication story

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1
The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
Group 2
The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
Group 3
The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amount of used anesthetic gas (desflurane)
Time Frame: Through study completion, an average of 2 month
Amount of used desflurane will be determined in milliliter by anesthesia machine (Maquet Flow i40) for each patient.
Through study completion, an average of 2 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart rate
Time Frame: Through study completion, an average of 2 month
Heart rate/min
Through study completion, an average of 2 month
Mean arterial pressure
Time Frame: Through study completion, an average of 2 month
Mean arterial pressure (mm/Hg)
Through study completion, an average of 2 month
Peripheral oxygen saturation
Time Frame: Through study completion, an average of 2 month
Peripheral oxygen saturation (%)
Through study completion, an average of 2 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yusuf Z Çolak, MD, Investigator

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2018

Primary Completion (Actual)

October 30, 2020

Study Completion (Actual)

March 1, 2021

Study Registration Dates

First Submitted

February 1, 2018

First Submitted That Met QC Criteria

March 13, 2018

First Posted (Actual)

March 14, 2018

Study Record Updates

Last Update Posted (Actual)

August 25, 2021

Last Update Submitted That Met QC Criteria

August 24, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • Inonu uni

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Safety Issues

Subscribe